Evidence map›Paper›PMID 42610056›Full record

ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2026

Serum GDF3 is Associated with Visceral Obesity, Insulin Resistance, and Inflammation in Non-Diabetic Adults: A Cross-Sectional Study with an Interventional Component.

Zhaozhi Li, Jiaoyang Li, Yun Ouyang, Liyan Jiang, Zhezhen Liao, Li Ran, Fei Yang, Xinhua Xiao, Yadi Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zhaozhi Li *Department of Metabolism and Endocrinology, The First Affiliated Hospital of University of South China, Hengyang, 421001, People's Republic of China.
Jiaoyang Li *Department of Metabolism and Endocrinology, The First Affiliated Hospital of University of South China, Hengyang, 421001, People's Republic of China.
Yun OuyangDepartment of Metabolism and Endocrinology, The First Affiliated Hospital of University of South China, Hengyang, 421001, People's Republic of China.
Liyan JiangDepartment of Metabolism and Endocrinology, The First Affiliated Hospital of University of South China, Hengyang, 421001, People's Republic of China.
Zhezhen LiaoDepartment of Metabolism and Endocrinology, The First Affiliated Hospital of University of South China, Hengyang, 421001, People's Republic of China.
Li RanDepartment of Metabolism and Endocrinology, The First Affiliated Hospital of University of South China, Hengyang, 421001, People's Republic of China.
Fei YangHunan Province Key Laboratory of Typical Environmental Pollution and Health Hazards, School of Public Health, University of South China, Hengyang, 421001, People's Republic of China.
Xinhua XiaoDepartment of Metabolism and Endocrinology, The First Affiliated Hospital of University of South China, Hengyang, 421001, People's Republic of China.
Yadi WangDepartment of Metabolism and Endocrinology, The First Affiliated Hospital of University of South China, Hengyang, 421001, People's Republic of China.ORCID 0000-0001-5916-6062

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Growth differentiation factor 3 (GDF3), a TGFβ superfamily cytokine, has been linked to visceral adipose proliferation and adiposity in animal studies. However, the relationship between circulating GDF3 levels and visceral adiposity in humans remains unclear. This study aimed to assess the potential of serum GDF3 as a biomarker for visceral obesity. Patients and Methods: This study comprised a cross-sectional component and an embedded self-controlled interventional component. A total of 282 adults aged 18-65 years were enrolled, including 162 individuals with visceral obesity and 120 without visceral obesity. Visceral obesity was defined as a visceral fat area (VFA) ≥ 100 cm Results: Serum GDF3 levels were significantly higher in adults with visceral obesity than in those without visceral obesity ( Conclusion: GDF3 may be a circulating biomarker of visceral obesity and a potential mediator linking visceral fat accumulation to related insulin resistance and inflammatory disturbances.

Indexed as

growth differentiation factor 3inflammationinsulin resistancesemaglutidevisceral obesity

Identifiers

PMID42610056
PMCPMC13480179

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.